

Cellular immune response in Dupuytren's disease

Original scientific article

Márk Plander^{1,2}, Antal Salamon³, Erzsébet Toldy^{1,4}, Gyula Kiss³, Gábor L. Kovács^{4,5}. Cellular immune response in Dupuytren's disease. *Biochemia Medica* 2008;18(2):193-200. <http://dx.doi.org/10.11613/BM.2008.019>

¹Central Laboratory, Markusovszky Teaching Hospital, Szombathely, Hungary

²Department of Haematology, Markusovszky Teaching Hospital, Szombathely, Hungary

³Department of Traumatology, Reconstructive and Hand Surgery, Markusovszky Teaching Hospital, Szombathely, Hungary

⁴Institute of Diagnostics and Management, University of Pécs, Pécs, Hungary

⁵Institute of Laboratory Medicine, University of Pécs, Pécs, Hungary

*Corresponding author: gabor.l.kovacs@aok.pte.hu

Abstract

Background: The pathogenesis of Dupuytren's disease is unclear, but inflammatory mechanisms might be supposed in the background.

Materials and methods: The ratios of the subsets of monocytes and lymphocytes in the peripheral blood were measured according to the stage of the disease of 39 Dupuytren's patients. They were compared with those of 29 healthy, age-matched controls. The measurements were accomplished by flow-cytometry.

Results: In an active stage, the patients had significantly increased ratios of monocytes, NK-like T-cells, whereas significantly decreased ratio of B-lymphocytes, including CD5+ B-cells. The ratios of CD4+, CD8+ T-cells and NK-cells did not change significantly. In the advanced stage, the ratios of monocytes and B-lymphocytes remained constant, but the ratios of T-cells decreased significantly. In four cases among Dupuytren's patients, mature B- or T-cell lymphoid malignancies occurred.

Conclusions: Our results support the previous considerations that lymphocytes are involved in the pathogenesis of Dupuytren's disease and enhance the role of

monocytes, NK-like T-cells and the alteration of immune response between the stages of the disease.

Key words: Dupuytren's disease, active and advanced stages, monocytes, NK-T cells

Received: December 27,

2008

April 18, 2008

Accepted:

Introduction

Dupuytren's disease (DD) is a chronic disorder, characterized by development of nodules and cords in the palmar and/or plantar aponeurosis. These pathologic changes arise from a fibrotic process, but the exact mechanism of contracture is unclear. Chiu and McFarlane (1) reported a clinical-pathological description; the three stages of the disease were recognised as early, active and advanced stages.

Previous reports have indicated that inflammatory mechanisms may be involved in the pathogenesis of DD. A number of authors reported that nodules contain inflammatory cells; mainly lymphocytes and macrophages (2). An increased frequency of activated (HLA-DR+) T-lymphocytes were also detected in the biopsied tissues (3). The elevated ratio of activated T-cells has been found in the peripheral blood of patients with DD, as well (4). The role of cytokines with T-cell origin was also proved. Transforming Growth Factor- β (TGF β) induces the transformation of fibroblasts into myofibroblasts that are responsible for the shrinkage of aponeurosis (2). A significant association was found between DD, HLA-DR3 and autoantibodies to types I-IV collagen (5).

Our aim was to investigate the participation of inflammatory mechanisms in the pathogenesis of DD and explore the distributions of monocytes and lymphocytes' subsets according to the stages of DD.

Materials and methods

Patients

A total of 39 adult male patients with DD aged between 45 and 69 (57 ± 12) years and a group of 29 age-matched, healthy male volunteers were included in this study. Those patients were excluded from the study, who suffered from any infection or from an internal disease as autoimmune disease, diabetes mellitus, cirrhosis hepatis, epilepsy, known malignancies. The patients were grouped according to the classification of Chiu and McFarlane on the basis of clinical and pathological classification, and were designated as early, active and advanced stages (1). 23

patients out of the whole Dupuytren's group were in active stage (stage 2) with nodular thickening of the palmar fascia associated with joint contracture. 16 patients were in advanced stage (stage 3) with progressive joint contracture. No patients were observed in the early group having nodule only in the palmar fascia (stage 1). In 36 cases only one hand was involved. Both hands were affected in 3 patients. The lesions were found essentially at the fourth and at the fifth ray. Patients were recruited at the Traumatology outpatient's room of Markusovszky Hospital in Szombathely. The sampling did take 2 years until 2007. The study was performed in accordance with the Helsinki Declaration and the research protocol was approved by the local ethical committee and all patients gave their informed consent to participate.

Immunophenotyping

Peripheral blood samples were taken into EDTA tubes and stained within 24 hours. Until staining procedure, specimens were stored at 4 °C. Fluorescence measurements were calibrated daily using standardized fluorescent surface labelled microspheres (FITC/PE). Standardization of cellular immunofluorescence relied on isotype control.

Cells were first counted and then diluted in PBS buffer to a concentration of approx. 10^7 /mL. Monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) were added in the recommended volume on the manufacturer's data sheet. The specificity and combinations of applied monoclonal antibodies were as follows: CD45/CD14, IgG1/IgG2 - isotype controls; CD3/CD19, CD3/CD16+56, CD3/CD4, CD3/CD8, CD5/CD20, CD3/HLA-DR, Kappa LC/CD19, Lambda LC/CD19. All reagents were purchased from BD Bioscience (San Jose, CA, USA). 100 μ L of diluted cell suspension was added to the prepipetted antibodies and incubated for 15 minutes on ice in the dark. Then, the erythrocytes were lysed at room temperature. Fluorescence data were acquired on a FACScan flow-cytometer and analyzed with CellQuest software (BD Bioscience). 10,000 events were collected from each sample.

Examples of the applied gating strategy are shown on Figure 1. To analyze the lymphocyte subpopulations, the lymphocytes (displayed in black) were gated on the basis of forward (FSC) and side scatter (SSC) (Figure 1A). Cytotoxic T-lymphocytes were discriminated by the coexpression of CD3 and CD8 antigens (Figure 1B), while helper T-lymphocytes by the coexpression of CD3 and CD4 antigens (Figure 1C). Natural Killer cells (NK) express CD16 and CD56 antigens in contrast to CD3, Natural Killer (NK)-type T-cells are CD3 and CD56 double positive (Figure 1D). B-lymphocytes bear CD20 antigen and partly CD5 antigen (Figure 1E).




Figure 1. The gating procedure. Lymphocytes were gated on the basis of forward (FSC) and side scatter (SSC) (Figure 1A). Cytotoxic T-lymphocytes are CD3 and CD8 double positive (upper right quadrant, Figure 1B). Helper T-cells express CD3 and CD4 together (upper right quadrant, Figure 1C). NK-cells bear CD56 and CD16 antigens (upper left

quadrant, Figure 1D), NK-T lymphocytes are positive for CD3 and CD56 antigens (upper right quadrant, Figure 1D). B-lymphocytes express CD20 and the B1 population also the CD5 antigen (upper right quadrant, Figure 1E).

Statistical analysis

Results are expressed in the percent of the total leukocyte number and in the calculated absolute cell-counts. Results are presented as mean \pm standard error (SE). One-way analysis of variance (ANOVA) was used for statistical analysis followed by a *post-hoc* paired comparison (LSD) test. A probability level of $<5\%$ was accepted as significance. Statistica for Windows program package was used for all statistical analysis, by 95% confidential interval.

Results

In 4 patients of the Dupuytren's group mature, indolent lymphoid malignancies, such as B-cell chronic lymphocytic leukaemia (CLL) and T cell granular lymphocytic leukaemia (T-LGL) were proved by immunoglobulin light chain restriction and/or abnormal immunophenotype, whilst such a disease was not found in the healthy group. The lymphomas were in an early stage without any clinical sign.

These haematological cases were excluded from the further analyses. The statistical differences among controls (N = 29), and patients in Dupuytren's stage 2 (N = 21) and stage 3 (N = 14) are shown in the Tables 1 and 2.

Table 1. Comparison of monocytes, B-lymphocytes and NK-cell counts between controls and Dupuytren patients.

	Monocytes (CD14+)	B-Ly (CD19+)	B1-Ly (CD20+5+)	NK-cells (CD16+56+)
	Mean \pm S.D. G/l (in % of the total WBC count)			
Control	0.37 \pm 0.10 (5.8 \pm 1.20)	0.20 \pm 0.06 (2.88 \pm 0.94)	0.09 \pm 0.05 (1.44 \pm 0.80)	0.20 \pm 0.10 (2.80 \pm 1.5)
Stage2	0.51 \pm 0.14** (7.5 \pm 1.7)	0.16 \pm 0.03* (2.13 \pm 1.01)	0.04 \pm 0.02*** (0.57 \pm 0.44)	0.22 \pm 0.14 (3.10 \pm 1.60)
Stage3	0.55 \pm 0.13** (8.10 \pm 2.90)	0.14 \pm 0.03** (1.93 \pm 1.15)	0.04 \pm 0.03*** (0.38 \pm 0.33)	0.23 \pm 0.15 (3.40 \pm 1.70)
ANOVA (P)	< 0.001	0.21	< 0.001	0.27

Significantly different from the control group by the LSD test: ***P < 0.001; **P < 0.01; *P < 0.05.

Table 2. Comparison of T-lymphocyte counts between controls and Dupuytren patients.

	T-Ly (CD3+)	NK T-Ly (CD3+56+)	Activated T-Ly (CD3+DR+)	T-helper (CD3+4+)	T-cytotoxic (CD3+8+)	CD3+4+/CD3+8+ ratio
Mean \pm S.D. G/I (in % of the total WBC count)						
Control	1.18 \pm 0.33 (18.80 \pm 4.20)	0.04 \pm 0.03 (0.66 \pm 0.54)	0.25 \pm 0.13 (3.80 \pm 1.80)	0.76 \pm 0.20 (12.10 \pm 2.50)	0.41 \pm 0.18 (6.40 \pm 2.70)	2.40 \pm 1.40
Stage2	1.38 \pm 0.37 (19.20 \pm 4.00)	0.08 \pm 0.05**b (1.07 \pm 0.80)	0.32 \pm 0.18 (4.70 \pm 3.40)	0.85 \pm 0.22 (13.00 \pm 4.10)	0.49 \pm 0.30 (7.10 \pm 4.90)	2.00 \pm 1.20
Stage3	1.06 \pm 0.42*a (16,10 \pm 5.20)	0.04 \pm 0.03*a (0.48 \pm 0.38)	0.23 \pm 0.08 (3.20 \pm 1.10)	0.68 \pm 0.33 (10.30 \pm 4.10)	0.38 \pm 0.17*a (5.80 \pm 2.30)	2.10 \pm 1.50
ANOVA (P)	0.21 (NS)	0.0016	0.07 (NS)	0.14 (NS)	0.24 (NS)	0.27 (NS)

a – Significantly different from stage 2; b – Significantly different from both the control and from stage 3 groups by the LSD test; **P < 0.01; *P < 0.05.

In both stages of Dupuytren's disease, the ratio of monocytes increased significantly as compared with the control group (5.75 \pm 0.21 vs. 7.49 \pm 0.35, P = 0.002, and 8.08 \pm 0.78, P < 0.001, respectively) and remained almost unchanged in the advanced stage (Table 1.). Natural Killer (NK)-type T-cells rose also significantly in stage 2 (0.66 \pm 0.09 vs. 1.07 \pm 0.16, P = 0.021), then fell in stage 3 (0.47 \pm 0.1 vs. 1.06 \pm 0.16, P = 0.012) (Table 2.). Table 1 depicts the significant reduction in B-lymphocytes (2.88 \pm 0.16 vs. 2.13 \pm 0.21 respectively, P = 0.013), including the B1 (CD 20+5+ coexpression) population (1.44 \pm 0.14 vs. 0.57 \pm 0.09, P = 0.009) in Dupuytren's patients compared with the healthy group. The ratio of B-lymphocytes did not change during the course of the disease. No statistically significant elevation were found in T-lymphocytes, including helper (CD4+), cytotoxic (CD8+) populations between stage 2 of Dupuytren's disease and healthy controls (Table 2). The ratio of CD4+/CD8+ T-cells fell in active stage (Table 2). Nevertheless, the percentage of entire T-lymphocyte population and that of helper T-cells was found to be significantly different between stages 2 and 3 of Dupuytren's patients (19.02 \pm 0.82 vs. 15.9 \pm 1.38, P = 0.043 and 13.04 \pm 0.85 vs. 10.27 \pm 1.09, P = 0.023, respectively) (Table 2). The ratios of cytotoxic T-, activated (HLA-DR+) T-cells and NK cells followed the alterations of helper T-lymphocyte populations, although neither of them changed significantly, the increase in HLA-DR+T lymphocytes show a strong tendency (P = 0.07) between the two DD groups (Table 1 and 2).

Discussion

We observed different and characteristic changes in numbers of peripheral blood lymphocytes and monocytes according to clinical stages of DD. In active stage, monocytes and NK-type T-cells increased significantly. Similarly, CD4+, CD8+, activated T-cells and NK-cells rose also, but these alterations were not significant. These findings support the previous observations that T-cells are involved in the pathogenesis of DD (3, 4). Monocytes, NK-T-cells and cellular immune response according to stages of DD were not investigated by this time.

These numbers are not the same as in Table 1.

A significant reduction of B-lymphocytes, including the so-called B1-cells (CD5+) was also here shown, which correlates partly with the results of Gudmundsson et al (4). They found a decrease in the ratio of CD5+ B-cells. Our previous observations about the presence of antinuclear antibodies refer also to the involvement of B-lymphocytes in DD (6). Fibrotic diseases, e.g. pulmonary fibrosis, hepatic fibrosis, systemic sclerosis are associated with anti-inflammatory T helper 2 (T_H2)-cell responses (7-10). TGFβ is one of the most important cytokines of T_H2 mediated immune response. The significance of TGFβ in Dupuytren's disease was proved by more authors (10-12). Macrophages are one of the main sources of TGFβ and macrophage-derived TGFβ is thought to be pro-fibrotic (13). Increased ratio of monocytes in DD may ensure permanent supply for macrophages in the affected tissue.

NKT-cells are able to secrete typical T_H2 cytokines, e.g. IL-13 (14). The activation of TGFβ1 depends on the matrix metalloproteinase-9 (MMP-9), upregulated by IL-13 that cleave the latency-associated peptide (15). In experimental models of autoimmune diseases, NKT cells protected from diabetes or experimental autoimmune encephalomyelitis by shifting the balance from T_H1 toward T_H2 response (16,17).

Patients with other fibrotic disease (e.g. systemic sclerosis) show similarly altered B-cell homeostasis to our results (18).

In the advanced stage, the ratios of CD4+ T-cells and NK-T-cells fell significantly, while that of CD8+ and HLA-DR+ T-cells decreased not significantly. The ratios of monocytes, B-lymphocytes remained constant compared with those in the active stage. The lowering tendency of T-cells is tempting to be speculated as part of an anti-inflammatory reaction that can be the final result of the T_H2 mediated immune response. Taken together, our data may refer to a T_H2 mediated immune response associated with massive fibrosis in the pathogenesis of DD. It should, however, be emphasized that by this time we have not investigated directly the cytokine profiles of T-cells in DD.

The frequent occurrence of mature, indolent lymphoid malignancies among our Dupuytren patients may support also the autoimmune hypothesis, because different autoimmune diseases, e.g. autoimmune haemolytic anaemia often complicate CLL. Of course, larger series are needed to justify an association between DD and haematological malignancies.

We conclude that monocytes, T- (especially NK-T) and B -lymphocytes are likely involved in the pathogenesis of Dupuytren's disease and alteration in their numbers

may refer to an ongoing inflammatory mechanism. Further studies, however, should be launched to investigate the aponeurosis infiltrating T-lymphocytes, the distribution and cytokine profile of the peripheral blood T-lymphocytes in early stage DD patients.

Acknowledgments

We are indebted to Rita Jáger M.D. at the Hungarian Blood Bank for control blood samples and to Mrs. J. Gál and Ms. M. Horváth for technical assistance.

References

1. Chiu HF, McFarlane RM. Pathogenesis of Dupuytren's contracture: A correlative clinical-pathological study. *J Hand Surg* 1978;3:1-10.
2. Thurston AJ. Dupuytren's disease. *J Bone Joint Surg* 2003;85:469-77.
3. Baird KS, Alwan HW, Crossan JF, Wojciak B. T-cell mediated response in Dupuytren's disease. *Lancet* 1993;341:1622-3.
4. Gudmundsson KG, Arngrimsson R, Arinbjarnarson S, Olafsson A, Jonsson T. T- and B-lymphocyte subsets in patients with Dupuytren's disease. *J Hand Surg* 1998; 23:724-7.
5. Neumüller J, Menzel J, Millesi H. Prevalence of HLA-DR3 and autoantibodies to connective tissue components in Dupuytren's contracture. *Clin Immunol Immunopathol* 1994;71:142-8.
6. Salamon A, Józsa L, Toldy E. The role of different factors in the pathogenesis of Dupuytren's disease. *Proceedings of the 8th Congress of the IFSSH*. 2001;363-9.
7. Dlugovitzky D, Bay ML, Rateni L, Urizar L, Rondelli CF, Largacha C, et al. In vitro synthesis of interferon-gamma, interleukin-4, transforming growth factor-beta and interleukin-1 beta by peripheral blood mononuclear cells from tuberculosis patients: relationship with the severity of pulmonary involvement. *Scand J Immunol* 1999;49:210-7.
8. Wallace WA, Ramage EA, Lamb D, Howie SE. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). *Clin Exp Immunol* 1995;101:436-41.
9. Vaillant B, Chiaramonte MG, Cheever AW, Soloway PD, Wynn TA. Regulation of hepatic fibrosis and extracellular matrix genes by the TH response: new insight into the role of tissue inhibitors of matrix metalloproteinases. *J Immunol* 2001;157:7017-26.

10. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10 and IL-13 in patients with systemic sclerosis. *J Rheumatol* 1997;24:328-32.
11. Bayat A, Stanley JK, Watson JS, Ferguson MW, Ollier WE. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. *Br J Plast Surg* 2003;56:328-33.
12. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Transforming growth factor-beta: possible roles in Dupuytren's contracture. *J Hand Surg* 1995;20:101-08.
13. Wynn AT. Fibrotic disease and the T_{H1}/T_{H2} paradigm. *Nat Rev Immunol* 2004;4:583-94.
14. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. *J Clin Invest* 2004;114:1379-88.
15. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Kotliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating the transforming growth factor $\beta 1$. *J Exp Med* 2001;194:809-21.
16. Hong S, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. Natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. *Nat Med* 2001;7:1052-6.
17. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. *J Exp Med* 2001;194:1789-99.
18. Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. *Curr Opin Rheumatol* 2005;17:746-51.